Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million.

Aslan Pharmaceuticals announced that new preclinical data characterizing ASLAN003 as a potential treatment for acute myeloid leukemia has been published in the November issue of Haematologica Journal which sent shares surging higher.

Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.

NJCTTQ, a Nanjing biopharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts.

China's life science sector started off 2019 with $425 million from ten deals involving Apollomics, Schrödinger of New York City and BrightGene Bio-Medical of Suzhou, among others.